Patent details

93274 Product Name: Elotuzumab

Basic Information

Publication number:
93274
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP101833770
Legal Status:
Active
Application number:
93274
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/16/1088
Marketing Authorization Type:
Marketing Authorization Date:
13/05/2016
Marketing Authorization Status:
Accepted
Marketing Authorization Country:

Dates

Filing date:
24/10/2016
First Marketing Authorization date:
13/05/2016
Grant date:
27/12/2016
Activation date:
10/05/2024
Publication date:
27/12/2016
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
10/05/2029
SPC Extension Expiration:
10/05/2029
Rejection date:
Withdrawal date:

Owner

From:
24/10/2016
 
 

Name:
ABBVIE BIOTHERAPEUTICS INC.
Address:
1500 SEAPORT BOULEVARD, REDWOOD CITY, CA 94063, United States (US)

Agent

Name:
DENNEMEYER & ASSOCIATES S.A. PATENT DEPARTMENT
From:
24/10/2016
Address:
PO Box 1502, 1015, LUXEMBOURG, Luxembourg (LU)
To:

Inventor

1

Name:
Tso Yun J.
Address:
United States (US)

2

Name:
Williams Marna
Address:
United States (US)

3

Name:
Liu Gao
Address:
United States (US)

4

Name:
Powers David B.
Address:
United States (US)

5

Name:
Landolfi Nicolas F.
Address:
United States (US)

Publication

Bulletin

Bulletin Heading:
SPC3
Bulletin edition number:
2025/04
Publication date:
04/03/2025
Description:
Section E : Supplementary Protection certificates entered into force – IA publication

Annual Fees

Annual Fee Due Date:
01/06/2026
Annual Fee Number:
23
Annual Fee Amount:
430 Euro
Expected Payer:
Last Annual Fee Payment Date:
19/03/2025
Last Annual Fee Paid Number:
22
Last Annual Fee Paid Amount:
420 Euro
Payer:
MASTER DATA CENTER INC (ex Clarivate Analytics)
Filing date Document type Number of pages